Companies /Healthcare

Boston Scientific Corp

NYSE: BSX Medical Devices
$48.30
â–² $1.46 (+3.12%) today
Markets closed · 6:42pm ET

Q2 2026 Earnings

Reported Jul 29, 2026, 6:33am ET · SEC source
$0.86
Beat +3.86%
EPS · est. $0.83
$5.4B
Beat +1.42%
Revenue · est. $5.4B
−3.7%
Trailing market
BSX vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−8%−4%0+4%Jul 29Jul 30report 6:33am ETearnings−0.5%−3.2%
−8%−4%0+4%Jul 29Jul 30earnings−0.5%−3.2%
BSX −3.2%S&P 500 −0.5%
−8%−4%0+4%Jul 29Jul 30report 6:33am ETearnings+0.5%−3.2%
−8%−4%0+4%Jul 29Jul 30earnings+0.5%−3.2%
BSX −3.2%NASDAQ +0.5%
−8%−4%0+4%Jul 28Aug 6report 6:33am ETearnings+3.9%+3.0%
−8%−4%0+4%Jul 28Aug 6earnings+3.9%+3.0%
BSX +3.0%S&P 500 +3.9%
−10%−5%0+5%Jul 28Aug 6report 6:33am ETearnings+5.6%+3.0%
−10%−5%0+5%Jul 28Aug 6earnings+5.6%+3.0%
BSX +3.0%NASDAQ +5.6%
−0.04%
Day of report
−0.09%
Next session
+3.69%
One week
+1.74%
30 days

S&P 500 over the same 30 days: +5.47%.

Did BSX Beat Earnings? Q2 2026 Results

Boston Scientific posted a clean beat across both top and bottom lines in Q2 2026, extending its EPS consensus beat streak to five consecutive quarters as adjusted earnings of $0.86 per share cleared the $0.83 estimate by 3.86% and rose sharply from $0.75 in the year-ago period. Revenue of $5.44 billion grew 7.5% year over year, edging past the $5.37 billion consensus by 1.42%, with the Cardiovascular segment serving as the primary engine, delivering 8.3% reported sales growth and helping lift GAAP net income to $907 million, or $0.61 per diluted share, from $797 million a year ago. A standout within the broader portfolio was the Neuromodulation business, which grew 12.7% on a reported basis, while the FARAPULSE pulsed field ablation system continued to generate positive clinical momentum. The strong quarter arrives alongside a global restructuring plan targeting $500 million in annual cost savings, as management looks to sharpen its operational profile; for full-year 2026, Boston Scientific guided for organic revenue growth of 5% to 6% and adjusted EPS of $3.28 to $3.32.

Key Takeaways
  • Cardiovascular segment growth of 8.3% reported driven by strong demand
  • Neuromodulation growth of 12.7% reported was the fastest growing product line
  • Asia Pacific region grew 11.2% and Latin America/Canada grew 22.4% on a reported basis
  • Category leadership strategy and disciplined execution across the portfolio

“Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.”

Boston Scientific CEO, on the earnings call

Forward Guidance & Outlook

For full year 2026, Boston Scientific estimates net sales growth of approximately 5.5% to 6.5% on a reported basis and 5% to 6% on an organic basis, with adjusted EPS of $3.28 to $3.32. For Q3 2026, the company estimates net sales growth of approximately 3% to 5% on both a reported and organic basis, with adjusted EPS of $0.80 to $0.82.

BSX YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$2.0B$4.0B$5.1B$5.4BRevenue$3.4B$3.8BGross Profit$819.0M$1.2BOperating Income$793.0M$907.0MNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income

BSX Revenue by Segment

Cardiovascular$3.6B+8.3%
Cardiology
MedSurg$1.8B+5.9%
Endoscopy$793.0M+7.6%
Urology$684.0M+1.1%
Peripheral Interventions
Neuromodulation$341.0M+12.7%

BSX Revenue by Geography

United States$3.4B+6.2%
EMEA$932.0M+6.1%
Asia Pacific$878.0M+11.2%
Latin America$206.0M+22.4%

Figures from SEC filings and company reports. Not investment advice.